Effects of induced hyperprolactinemia on in vitro fertilization cycles

What Was Tested

This controlled clinical trial paper looks at hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin) in the context of hyperparathyroidism.

To investigate the effect of induced endogenous hyperprolactinemia on the luteinization process, as expressed by the shift in the P:E2 ratio after hCG injection in IVF cycles.

Who Took Part

The study group was 49 patients.

PubMed tags the participants as women only.

Serum PRL, E2, and P levels were measured in 49 IVF patients (leuprolide acetate and hMG protocol) on the day of hCG injection.

Serum P:E2 ratios were calculated for two groups of patients; group I (control): PRL < or = 20 ng/mL (conversion factor to SI unit, 1.00); group II (hyperprolactinemia): PRL > 20 ng/mL.

How the Study Was Run

Estradiol and P also were measured on the day after hCG.

Estradiol and P also were measured in follicular fluid (FF) and the gamete performance was compared between groups.

What Was Measured

PubMed files the paper under topics including Chorionic Gonadotropin, Estradiol, Fertilization in Vitro, Follicular Fluid, Hyperprolactinemia, Leuprolide and Menotropins.

What This Means in Plain Language

This is a controlled clinical trial of hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin) in 49 patients in people with hyperparathyroidism.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1995 (Fertility and sterility), a journal based in United States.

More context: the hCG (human chorionic gonadotropin) compound page and the HMG (Human Menopausal Gonadotropin) compound page, Hyperparathyroidism research.